Recent studies in the *Lancet* ([@bib1]; [@bib18], [@bib19]) have reinforced interest in the potential value of using NSAIDs, such as aspirin, in colorectal cancer chemoprevention. Over much of the last few decades, a major focus of colorectal cancer chemoprevention has been inhibition of COX-2, an inducible cyclooxygenase isoform that is upregulated at the medium/large adenoma stage, and to which the elevated levels of the protumorigenic prostaglandin PGE~2~ have previously been attributed ([@bib17]; [@bib5]; [@bib6]). However, several lines of evidence suggest a potential role for COX-1 in colorectal neoplasia. For example, tumorigenesis in animal models can be suppressed by deletion of either *COX-1* or *COX-2* genes ([@bib4]), or by administration of a COX-1-selective inhibitor ([@bib10]), though the precise role of COX-1 in intestinal neoplasia is unclear. Our recent paper in *Gut* ([@bib20]) highlighted a mechanism by which COX-1 could contribute to early colorectal cancer development. We showed that *β*-catenin, activated at the earliest stages of colorectal neoplasia, can repress expression of the colorectal tumour suppressor and prostaglandin catabolising enzyme 15-prostaglandin dehydrogenase (15-PGDH). Here, we now show that *β*-catenin also represses expression of a second gene crucial for prostaglandin catabolism, the prostaglandin transporter PGT. PGT (aka SLCO2A1) mediates uptake of secreted prostaglandins, enabling their oxidative inactivation by cytoplasmic 15-PGDH ([@bib14]). Like 15-PGDH, downregulation of PGT has been reported in both human colorectal tumours and in pre-malignant adenomas in APC^min/+^ mice, and this was suggested to result, at least in part, from epigenetic silencing ([@bib8]). However, we hypothesised that *β*-catenin may also have a role in repression of PGT expression in colorectal cancer, as we reported previously for 15-PGDH. Here we show that modulating *β*-catenin expression or function increases PGT expression, both in the intestinal epithelium *in vivo*, and in colorectal adenoma and carcinoma cells *in vitro*. Our data suggest that *β*-catenin co-ordinately regulates prostaglandin turnover through the negative regulation of both PGT and 15-PGDH expression, and highlight a potential mechanism that could contribute to the chemopreventive efficacy of the non-selective NSAID aspirin.

Materials and methods
=====================

The colon carcinoma-derived cell lines HCT15, HCT116, HT29, LOVO, LS174T, SW480 and SW620, obtained from the American Type Culture Collection (Rockville, MD, USA); the HCA7 colony 29 (HCA7) colon carcinoma cell line, a kind gift of Susan Kirkland ([@bib9]); the dox-inducible dnTCF4-expressing LS174T/dnTCF4 cell line, a kind gift from Hans Clevers ([@bib21]); and colon adenoma-derived cell lines PC/AA/C1, PC/AA/C1/SB10C, PC/BH/C1, S/AN/C1 and S/RG/C2 derived in this laboratory ([@bib15], [@bib16]; [@bib22]) were maintained as described previously ([@bib15]; [@bib13]), except for PC/AA/C1 and PC/AA/C1/SB10C, which were maintained on conditioned medium ([@bib22]). Immunohistochemical staining using a rabbit polyclonal PGT antibody (kind gift of Michel Fortier, Quebec, Canada) and inducible intestinal *β*-catenin ablation in mice were carried out and validated as previously described ([@bib20]), as was intestinal epithelial cell fractionation (see also [@bib12]). RNA interference, immunoblotting and mRNA preparation were also performed as previously described ([@bib20]). Semi-quantitative RT-PCR was carried out as in [@bib3], with minor modifications, and quantitative real-time RT-PCR was carried out as described previously ([@bib13]), using PGT primers from Qiagen (Crawley, West Sussex, UK).

Results
=======

Preliminary studies suggested that, similar to 15-PGDH, PGT also shows an expression gradient in the human intestinal epithelium, being highest in the differentiated luminal/villus compartment ([Figure 1A](#fig1){ref-type="fig"}). A similar PGT expression gradient was also observed in the murine small intestinal epithelium, both at the mRNA ([Figure 1B](#fig1){ref-type="fig"}) and protein level ([Figure 1C](#fig1){ref-type="fig"}). As Wnt/*β*-catenin transcriptional activity is known to be highest in the proliferative crypt compartment ([@bib21]; [@bib11]), we hypothesised that PGT may also be repressed by *β*-catenin in intestinal epithelial cells. Importantly, the gradient of PGT expression was lost following inducible *β*-catenin ablation ([Figure 1D](#fig1){ref-type="fig"}; [@bib7]). Elevated PGT expression was particularly noticeable in crypt epithelia (compare [Figure 1F with E](#fig1){ref-type="fig"}), where *β*-catenin activity is normally highest ([@bib2]; [@bib21]). This increase is consistent with previously published microarray analysis (1.67-fold increase, [@bib7]), confirming that *β*-catenin represses PGT expression in the normal murine intestinal epithelium.

We then hypothesised that *β*-catenin may also repress PGT expression in human colorectal cancer cells, as is the case for 15-PGDH. Indeed, in line with this hypothesis, basal PGT levels are reportedly very low to undetectable in most colorectal carcinoma cell lines ([@bib8]). We confirmed and extended this observation to include cell lines derived from sporadic (S/RG/C2, S/AN/C1) and familial adenomatous polyposis patient (PC/AA/C1, PC/BH/C1) adenomas and one *in-vitro*-transformed adenoma cell line (PC/AA/C1/SB10C) ([Figure 2A](#fig2){ref-type="fig"}). Indeed, in our hands, PGT mRNA was only readily detectable in LoVo carcinoma-derived and PC/BH/C1 adenoma-derived cells under basal conditions. Notably, siRNA-mediated knockdown of *β*-catenin increased PGT mRNA expression in both adenoma- and carcinoma-derived cell lines ([Figure 2B and C](#fig2){ref-type="fig"}). In addition, PGT mRNA levels were consistently increased in the colorectal carcinoma cell line LS174T/dnTCF4, 48 h following induction of dnTCF4, a dominant-negative form of this *β*-catenin-binding partner that is unable to bind *β*-catenin ([Figure 2D and E](#fig2){ref-type="fig"}). Hence, taken together, these data suggest that *β*-catenin represses PGT expression in both the normal intestinal epithelium and in colorectal cancer.

Discussion
==========

In this article, we have identified a novel link between two important pathways in colorectal neoplasia, Wnt/*β*-catenin and PGE~2~ signalling, through the negative regulation of PGT expression. Therefore, similar to 15-PGDH, PGT expression could be widely downregulated at a very early stage of colorectal neoplasia in sporadic tumours as well as those arising in the context of a germline APC mutation. Downregulation of PGT, in addition to 15-PGDH, may constitute a very effective means of increasing local PGE~2~ levels as impaired PGT-mediated prostaglandin import would be expected to directly increase extracellular prostaglandin concentrations available to interact with cell surface receptors.

The ability of *β*-catenin to downregulate both 15-PGDH and PGT, two crucial regulators of prostaglandin catabolism, points towards the importance of elevated COX-1-derived prostaglandin levels during early colorectal neoplasia before COX-2 upregulation, and may go some way to explain the particular efficacy in colorectal cancer chemoprevention of the non-selective NSAID aspirin.
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![(**A**, **B**) Gradient of PGT protein and mRNA expression with differentiation along the crypt--villus axis in intestinal epithelium. (**A**) PGT immunohistochemistry shows high PGT expression in the differentiated human villus epithelium. Scale bar represents 50 *μ*m. (**B**) Differential fractionation of the murine intestinal epithelium followed by microarray gene expression analysis ([@bib12]) shows that, like the differentiation marker villin, PGT mRNA expression increases along the crypt--villus axis. In contrast, expression of the proliferation marker PCNA and the Wnt/*β*-catenin target c-Myc both decrease along the crypt--villus axis. Data represents expression relative to fraction 10 in fractions 10, 8, 6, 4, 2 and 1. This gradient of PGT expression is confirmed at the protein level by immunohistochemistry (see **C**). (**C**--**F**) Inducible *β*-catenin ablation increases crypt epithelial PGT expression levels. Deletion of *β*-catenin was induced in *β*-catenin^−/lox^-villin-creERT2 mice by tamoxifen injection (**D**, **F**); injected *β*-catenin^+/lox^-villin-creERT2 mice (**C**, **E**) were used as a control. PGT staining shows PGT expression throughout the crypt--villus axis in the absence of *β*-catenin (**D**), particularly evident in crypt and lower villus epithelium (**F** as compared with **E**) (representative examples from 96 h post induction). Scale bars represent 50 *μ*m.](bjc2012430f1){#fig1}

![(**A**) PGT mRNA expression screen in colorectal adenoma- and carcinoma-derived cell lines. PC/AA/C1, S/AN/C1, PC/BH/C1 and S/RG/C2 are adenoma-derived cell lines, PC/AA/C1/SB10C is an *in-vitro*-transformed adenoma-derived cell line and the remainder are carcinoma-derived. Semi-quantitative real-time PCR analysis confirmed that most colorectal carcinoma-derived cell lines express low levels of PGT with the exception of LoVo. Interestingly, a similar pattern was seen in our adenoma-derived cell lines, with mostly very low expression with the exception of PC/BH/C1 cells (NTC=no template control, −RT=no reverse transcriptase enzyme control). (**B**, **C**) *β*-catenin siRNA knockdown increases PGT expression. (**B**) Immunoblotting (IB) demonstrating that transient *β*-catenin siRNA transfection effectively reduced *β*-catenin protein levels in S/RG/C2, SW480 and LoVo cell lines (48 h). Semi-quantitative PCR analysis (PCR) revealed a marked and consistent increase in PGT mRNA levels in S/RG/C2, SW480 and LoVo cells following *β*-catenin siRNA-mediated knockdown (48 h). (**C**) Quantitative real-time PCR analysis confirms the increase in PGT mRNA apparent in **B**. (**D**) Induction of dnTCF4 increases PGT expression immunoblotting demonstrates effective induction in LS174T/dnTCF4 cells of dnTCF4 with 1 *μ*g ml^−1^ doxycycline (dox; 48 h). Semi-quantitative PCR analysis (PCR) demonstrates a consistent increase in PGT mRNA levels in LS174T/dnTCF4 cells following dox-mediated induction of dnTCF4 (48 h). (**E**) Quantitative real-time PCR analysis confirms the increase in PGT mRNA apparent in **D**. Results shown are representative of a minimum of three independent repeat experiments. *α*-tubulin and *β*-actin serve as loading controls.](bjc2012430f2){#fig2}
